Skip to content

US · CABA · BIOTECHNOLOGY

Cabaletta Bio, Inc. (CABA) intrinsic value and stock valuation

$0.94as of 2026-11-21 · Mkt cap 454.92M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cabaletta Bio, Inc. DCF and intrinsic value

InvestorsCraft values CABA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CABA’s statements →

Cabaletta Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Philadelphia, PA 19104 cabalettabio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-167.86M
20172025
Free cash flow
-$-132.31M
20172025
Total equity
$112.1M+0.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-172.24M-$-125.14M-$-74.66M-$-54.14M-$-46.31M
Net income-$-167.86M-$-115.86M-$-67.67M-$-52.98M-$-46.29M
EPSd-$-1.64M-$-2.34M-$-1.65M-$-1.81M-$-1.8M
Operating cash flow-$-131.08M-$-88.22M-$-53.55M-$-46.38M-$-34.11M
Capital expenditure-$-1.23M-$-2.21M-$-690K-$-2.45M-$-1.17M
Free cash flow-$-132.31M-$-90.43M-$-54.24M-$-48.83M-$-35.27M
Total assets$165.1M$185.1M$253.7M$117M$126.3M
Total debt$27.1M$15.6M$5.02M$5.14M$0.00
Net debt-$-55.88M-$-148.36M-$-188.22M-$-76.47M-$-122.22M
Total equity$112.1M$152.3M$236.2M$104.5M$118M
Cash and short-term investments$133.6M$164M$241.3M$106.6M$122.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$142.7M$97.2M$55.4M$39.3M$32.5M
Selling, general and administrative expenses$29.6M$27.9M$19.2M$14.8M$13.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$172.2M$125.1M$74.7M$54.1M$46.3M
Cost and expenses$172.2M$125.1M$74.7M$54.1M$46.3M
Interest income$6.03M$10M$6.99M$1.16M$20K
Interest expense$2M$750K$0.00$0.00$0.00
Depreciation and amortization$1.65M$1.71M$1.43M$1.18M$730K
Ebitda-$-164.21M-$-113.41M-$-66.25M-$-51.8M-$-45.56M
Operating income-$-172.24M-$-125.14M-$-74.66M-$-54.14M-$-46.31M
Total other income/expenses, net$4.38M$9.28M$6.99M$1.16M$20K
Income before tax-$-167.86M-$-115.86M-$-67.67M-$-52.98M-$-46.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-167.86M-$-115.86M-$-67.67M-$-52.98M-$-46.29M
Weighted average shares outstanding$102.3M$49.5M$41M$29.3M$25.7M
Weighted average diluted shares outstanding$102.3M$49.5M$41M$29.3M$25.7M
Balance sheet
20252024202320222021
Cash and short-term investments$133.6M$164M$241.3M$106.6M$122.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$138.9M$166.7M$244.5M$108.8M$124.5M
Property, plant and equipment, net$21.1M$16.1M$7.45M$7.57M$1.44M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$26.2M$22.3M$9.16M$8.13M$1.79M
Total assets$165.1M$185.1M$253.7M$117M$126.3M
Accounts payable$6.64M$4.92M$4.55M$2.46M$2.33M
Short-term debt$24.2M$9.97M$3.56M$2.18M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$50.2M$27.1M$16M$9.49M$8.38M
Long-term debt$2.88M$5.62M$1.46M$2.96M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.88M$5.62M$1.46M$2.96M$0.00
Capital lease obligations$24.2M$15.6M$5.02M$5.14M$0.00
Total liabilities$53M$32.7M$17.5M$12.5M$8.38M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-516.96M-$-349.1M-$-233.24M-$-165.56M-$-112.59M
Accumulated other comprehensive income (loss)$30K$0.00$40K-$-50K$0.00
Total equity$112.1M$152.3M$236.2M$104.5M$118M
Total investments$50.6M$0.00$48M$24.9M$0.00
Total debt$27.1M$15.6M$5.02M$5.14M$0.00
Net debt-$-55.88M-$-148.36M-$-188.22M-$-76.47M-$-122.22M
Cash flow statement
20252024202320222021
Net income-$-167.86M-$-115.86M-$-67.67M-$-52.98M-$-46.29M
Depreciation and amortization$1.65M$1.71M$1.43M$1.18M$730K
Stock-based compensation$20.9M$19.5M$11.3M$6.9M$5.8M
Change in working capital-$-380K$1.61M$100K-$-4.3M$5.58M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.55M$1.01M$1.68M-$-30K$970K
Net cash provided by operating activities-$-131.08M-$-88.22M-$-53.55M-$-46.38M-$-34.11M
Investments in property, plant and equipment-$-1.23M-$-2.21M-$-690K-$-2.45M-$-1.17M
Acquisitions, net$0.00$0.00$0.00$20K$0.00
Net cash used for investing activities-$-50.27M$47.3M-$-22.45M-$-27.22M$6M
Common stock issued$106.6M$10.9M$185.2M$32.9M$48.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$100.4M$11.7M$187.6M$33M$48.9M
Net change in cash-$-80.98M-$-29.28M$111.6M-$-40.62M$20.8M
Cash at end of period$83M$164M$193.2M$81.6M$122.2M
Operating cash flow-$-131.08M-$-88.22M-$-53.55M-$-46.38M-$-34.11M
Capital expenditure-$-1.23M-$-2.21M-$-690K-$-2.45M-$-1.17M
Free cash flow-$-132.31M-$-90.43M-$-54.24M-$-48.83M-$-35.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cabaletta Bio, Inc.

        Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.

        CEO
        Steven A. Nichtberger
        Employees
        156
        Beta
        3.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Cabaletta Bio, Inc. (CABA)?

        InvestorsCraft does not currently publish an intrinsic value for CABA. How the IC value is calculated.

        Is CABA undervalued?

        InvestorsCraft does not publish an undervaluation signal for CABA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.